These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8653152)

  • 1. The effect of withdrawal and re-introduction of dexfenfluramine in the treatment of obesity.
    Ditschuneit HH; Flechtner-Mors M; Adler G
    Int J Obes Relat Metab Disord; 1996 Mar; 20(3):280-2. PubMed ID: 8653152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
    O'Connor HT; Richman RM; Steinbeck KS; Caterson ID
    Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss.
    Breum L; Møller SE; Andersen T; Astrup A
    Int J Obes Relat Metab Disord; 1996 Feb; 20(2):147-53. PubMed ID: 8646251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial.
    Andersen T; Astrup A; Quaade F
    Int J Obes Relat Metab Disord; 1992 Jan; 16(1):35-40. PubMed ID: 1314242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged surveillance of dexfenfluramine in severe obesity.
    Mathus-Vliegen EM
    Neth J Med; 1993 Dec; 43(5-6):246-53. PubMed ID: 8107932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice.
    Breum L; Pedersen JK; Ahlstrøm F; Frimodt-Møller J
    Int J Obes Relat Metab Disord; 1994 Feb; 18(2):99-103. PubMed ID: 8148931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tolerance and acceptability of dexfenfluramine in the long-term treatment of obesity in private practice. ESIM Group].
    Héraïef E
    Rev Med Suisse Romande; 1997 Jan; 117(1):19-24. PubMed ID: 9082531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged weight loss with dexfenfluramine treatment in obese patients.
    Finer N; Craddock D; Lavielle R; Keen H
    Diabete Metab; 1987; 13(6):598-602. PubMed ID: 3329122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom.
    Finer N; Craddock D; Lavielle R; Keen H
    Clin Neuropharmacol; 1988; 11 Suppl 1():S179-86. PubMed ID: 3052816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International trial of long-term dexfenfluramine in obesity.
    Guy-Grand B; Apfelbaum M; Crepaldi G; Gries A; Lefebvre P; Turner P
    Lancet; 1989 Nov; 2(8672):1142-5. PubMed ID: 2572857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine.
    Pfohl M; Luft D; Blomberg I; Schmülling RM
    Int J Obes Relat Metab Disord; 1994 Jun; 18(6):391-5. PubMed ID: 8081430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body weight evolution during dexfenfluramine treatment after initial weight control.
    Finer N
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 3():S25-9. PubMed ID: 1338319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of dexfenfluramine treatment in obese adolescents].
    Małecka-Tendera E; Koehler B; Muchacka M; Wazowski R; Trzciakowska A
    Pediatr Pol; 1996 May; 71(5):431-6. PubMed ID: 8710426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors.
    Swinburn BA; Carmichael HE; Wilson MR
    Int J Obes Relat Metab Disord; 1996 Nov; 20(11):1033-40. PubMed ID: 8923161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine and metabolic effects of dexfenfluramine in patients with android obesity.
    Ditschuneit HH; Flechtner-Mors M; Dolderer M; Fulda U; Ditschuneit H
    Horm Metab Res; 1993 Nov; 25(11):573-8. PubMed ID: 8288160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical observations on the treatment of obese patients with dexfenfluramine].
    Cairella M; Pisculli M; Petraroli AR; Riganelli S; Saracino A; Siani V
    Clin Ter; 1990 Jun; 133(5):289-97. PubMed ID: 2143712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A close look at fenfluramine and dexfenfluramine.
    Vivero LE; Anderson PO; Clark RF
    J Emerg Med; 1998; 16(2):197-205. PubMed ID: 9543401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexfentluramine in the treatment of juvenile obesity.
    Grugni G; Guzzaloni G; Ardizzi A; Moro D; Morabito F
    Minerva Pediatr; 1997 Mar; 49(3):109-17. PubMed ID: 9198730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INDEX (international dexfenfluramine study) as a model for long-term pharmacotherapy of obesity in the 1990s.
    Guy-Grand B
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 3():S5-14. PubMed ID: 1338322
    [No Abstract]   [Full Text] [Related]  

  • 20. [International study of the effect of dexfenfluramine in obesity (ISIS): 6 months' results].
    Guy-Grand B; Apfelbaum M; Crepaldi G; Gries A; Lefebvre P; Turner P
    Rev Med Interne; 1989; 10(3):271-7. PubMed ID: 2669089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.